Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele

1999 ◽  
Vol 81 (06) ◽  
pp. 991-992 ◽  
Author(s):  
K. Paciaroni ◽  
P. Chiusolo ◽  
I. Casorelli ◽  
E. Rossi ◽  
L. Teofili ◽  
...  
Keyword(s):  
Oral Contraceptives ◽  
Cerebral Vein ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis ◽  
Prothrombin 20210A

Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis

1996 ◽  
Vol 76 (03) ◽  
pp. 477-478 ◽  
Author(s):  
I Martinelli ◽  
F R Rosendaal ◽  
J P Vandenbroucke ◽  
P M Mannucci
Keyword(s):  
Risk Factor ◽  
Oral Contraceptives ◽  
Cerebral Vein ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis

Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis

Blood ◽  
2006 ◽  
Vol 107 (7) ◽  
pp. 2766-2773 ◽  
Author(s):  
Francesco Dentali ◽  
Mark Crowther ◽  
Walter Ageno
Keyword(s):  
Oral Contraceptives ◽  
Meta Analysis ◽  
Factor V Leiden ◽  
Cochrane Library ◽  
Cerebral Vein ◽  
Factor V ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Study Characteristics

AbstractRecent studies suggest that thrombophilic abnormalities and the use of oral contraceptives (OCs) are the leading causes of cerebral vein thrombosis (CVT). The purpose of this study was to assess the association between CVT and thrombophilic states, OCs, and their interaction. For data sources, we used the MEDLINE, EMBASE, and Cochrane Library databases (January 1994 to March 2005), reference lists of retrieved articles, and contact with content experts. We selected studies comparing the prevalence of OC use and the prevalence of prothrombitic abnormalities in patients with CVT compared with healthy controls. Two reviewers independently selected studies and extracted study characteristics, quality, and outcomes. Odds ratios (ORs) were calculated for each trial and pooled using the Mantel-Haenszel method. Seventeen studies were included. There was an increased risk of CVT in patients using OCs (OR 5.59; 95% confidence interval [CI] 3.95 to 7.91; P < .001), and in patients with factor V Leiden (OR 3.38; 95% CI 2.27 to 5.05; P < .001), with mutation G20 210A of prothrombin (OR 9.27; 95% CI 5.85 to 14.67; P < .001) and with hyperhomocysteinemia (OR 4.07; 95% CI 2.54 to 6.52; P < .001). We concluded that OC users, and patients with factor V Leiden, the prothrombin G20 120A mutation, and hyperhomocysteinemia are at a significantly increased risk of CVT.

Risk of cerebral vein thrombosis and oral contraceptives

The Lancet ◽  
1998 ◽  
Vol 352 (9124) ◽  
pp. 326 ◽  
Author(s):  
I Martinelli ◽  
E Taioli ◽  
D Palli ◽  
PM Mannucci
Keyword(s):  
Oral Contraceptives ◽  
Cerebral Vein ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis

High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation and in Users of Oral Contraceptives

1998 ◽  
Vol 338 (25) ◽  
pp. 1793-1797 ◽  
Author(s):  
Ida Martinelli ◽  
Elisabetta Sacchi ◽  
Gianluca Landi ◽  
Emanuela Taioli ◽  
Francesca Duca ◽  
...  
Keyword(s):  
High Risk ◽  
Gene Mutation ◽  
Oral Contraceptives ◽  
Cerebral Vein ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis ◽  
Prothrombin Gene Mutation ◽  
Prothrombin Gene

scholarly journals Convexity subarachnoid hemorrhage: clinical features and etiology of an Argentinian cohort

2017 ◽  
Vol 75 (12) ◽  
pp. 858-861 ◽  
Author(s):  
Aníbal Chertcoff ◽  
Lucrecia Bandeo ◽  
Fátima Pantiu ◽  
Luciana León Cejas ◽  
Sol Pacha ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Clinical Features ◽  
Wide Spectrum ◽  
Amyloid Angiopathy ◽  
Cerebral Vein ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis ◽  
Cerebral Vasoconstriction ◽  
Subarachnoid Bleeding ◽  
Cerebral Amyloid

ABSTRACT Nontraumatic convexity subarachnoid hemorrhage is an increasingly recognized subtype of subarachnoid bleeding. Objective: Our aim was to describe the etiology and clinical features of a cohort of patients with convexity subarachnoid hemorrhage. Methods: We retrospectively analyzed all cases of convexity subarachnoid hemorrhage admitted to our hospital between January 2012 and April 2017. Demographic features, clinical characteristics, complementary investigations, etiology and mortality were assessed. Twenty patients (65% females) were identified. Mean age: 53 years (range, 15-86 years). Results: Symptoms on admission: headache (65%), sensory and/or motor symptoms (50%) and seizures (35%). Commonest causes: cerebral vein thrombosis (20%), reversible cerebral vasoconstriction syndrome (20%) and cerebral amyloid angiopathy (20%). Two patients died. Conclusion: Convexity subarachnoid hemorrhage may be related to a wide spectrum of etiologies. In our patients, an increased prevalence of cerebral vein thrombosis was observed. Mortality was low and not related to the bleeding itself.

scholarly journals Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature

2021 ◽  
Vol 11 (12) ◽  
pp. 1641
Author(s):  
Alba Jerez-Lienas ◽  
Alexis Mathian ◽  
Jenifer Aboab ◽  
Isabelle Crassard ◽  
Miguel Hie ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Medical Records ◽  
Case Reports ◽  
Case Series ◽  
Autoimmune Disorder ◽  
Point Of View ◽  
Cerebral Vein ◽  
Review Of The Literature ◽  
Cerebral Vein Thrombosis ◽  
Vein Thrombosis

(1) Background: The Antiphospholipid Syndrome (APS) is a systemic autoimmune disorder characterized by arterial and/or venous thrombosis, pregnancy morbidity and raised titers of antiphospholipid antibodies. Cerebral vein thrombosis (CVT) is a rare form of cerebrovascular accident and an uncommon APS manifestation; the information in the literature about this feature consists of case reports and small case series. Our purpose is to describe the particular characteristics of CVT when occurs as part of the APS and compare our series with the patients published in the literature. (2) Methods: We conducted a retrospective observational study collecting data from medical records in three referral centers for APS and CVT, and a systematic review of the literature for CVT cases in APS patients. (3) Results: Twenty-seven APS patients with CVT were identified in our medical records, the majority of them diagnosed as primary APS and with the CVT being the first manifestation of the disease; additional risk factors for thrombosis were identified. The review of the literature yielded 86 cases, with similar characteristics as those of our retrospective series. (4) Conclusions: To our knowledge, our study is the largest CVT series in APS patients published to date, providing a unique point of view in this rare thrombotic manifestation.

Sign in / Sign up

Export Citation Format

Share Document